Core Insights - The 32nd China SAE Congress & Exhibition highlighted advancements in solid-state battery technology, particularly by BAK Battery, showcasing its transition from R&D to industrial applications [1] - The solid-state battery market is projected to grow significantly, with global shipments expected to reach 614.1 GWh by 2030, surpassing RMB 100 billion, primarily driven by semi-solid cells [3] - BAK's semi-solid-state batteries are designed to enhance safety and performance while facilitating mass production, making them a practical step towards fully solid-state technology [4] Company Developments - BAK Battery's in-situ solidification method reduces liquid electrolyte to under 10%, achieving high safety standards and maintaining ionic conductivity, with pilot lines producing cells ranging from 43Ah to 70Ah [5] - The company's semi-solid-state batteries have demonstrated reliability in various applications, including security, eVTOL, two-wheelers, and electric vehicles, with specific performance metrics such as 300-400Wh/kg cells retaining ≥80% capacity after 1,000 cycles [6][7] - BAK's strategy focuses on addressing real-world needs through technological advancements and product upgrades, ensuring that their semi-solid-state technology aligns with market demands [5][7]

Core Insights - Volta Finance Limited reported a net performance of +0.3% for September 2025, bringing the year-to-date performance to +3.5% [4] - The performance of Volta Finance is lower compared to US High Yield and Euro High Yield, which returned +7.1% and +4.6% respectively [4] - The company's NAV as of the end of September 2025 was €272.6 million, equating to €7.45 per share [8] Market Overview - Global markets demonstrated resilience, with US equities benefiting from investments in artificial intelligence and anticipated interest rate cuts by the Federal Reserve [5] - Fixed income yields increased, with long-term rates in France and Germany reaching multi-year highs, while UK gilts advanced ahead of the Autumn Budget [5] - The Federal Reserve executed its first rate cut in nine months, while the ECB and Bank of England maintained a cautious approach [5] Portfolio Activity - Volta Finance reinvested approximately €10 million into five different US and European BB and B CLO debts, reducing its cash position from 18% to 16% [7] - The company experienced stable interest and coupon generation over the past six months, amounting to about €28 million equivalent, or approximately 21% of September NAV on an annualized basis [7] - Volta's CLO Equity tranches returned +0.3%, while CLO Debt tranches returned +1.2% during the month [8] Investment Strategy - Volta Finance aims to preserve capital across the credit cycle and provide a stable income stream to shareholders through quarterly dividends [13] - The company primarily seeks exposure to CLOs and similar asset classes, with a potential for a more diversified investment strategy across structured finance assets [13]

24 October 2025 | SAINT HELIER, Jersey | CoinShares International Limited ("CoinShares" or "the Group") (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European asset manager specialising in digital assets, announces a change to its financial calendar following the receipt of a waiver granted by Nasdaq Stockholm regarding publication of the Group’s financial results for the interim period 1 January – 30 September, 2025 (Q3). As a result of this waiver, CoinShares will not publish its financial results ...

Core Insights - Izotropic Corporation is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the AI-driven imaging sector targeting the breast cancer market [1][2]. Industry Overview - The healthcare sector is experiencing significant transformation due to artificial intelligence, particularly in medical imaging, which is crucial for breast cancer detection [2]. - Breast cancer is the most commonly diagnosed cancer among women globally, with over 2.3 million diagnoses and approximately 670,000 deaths reported by the World Health Organization in 2022 [2]. - In the United States, the American Cancer Society estimates 316,950 new invasive breast cancer cases for the current year [2]. Company Highlights - Izotropic Corporation is developing the IzoView Breast CT Imaging System, a specialized 3D imaging solution aimed at improving cancer detection accuracy, especially in women with dense breast tissue [3]. - The company focuses on innovative technologies and imaging products for more accurate screening, diagnosis, and treatment of breast cancers [4].

Core Insights - Vystar Corporation has initiated coverage by the Internet and Incubator Stock Review, highlighting its portfolio of start-ups and development assistance strategy aimed at achieving profitability for each company [1][2]. Company Overview - Vystar Corporation is based in Worcester, Massachusetts, and owns RxAir UV light air purification products, Vytex Natural Rubber Latex, and is a partner/investor in GoPaid.com and Fluid Energy Solutions [10]. - The company has developed a multi-patented, environmentally safe rubber product, Vytex, which is used in various consumer and medical applications [10]. Product Highlights - The RxAir 400 model, a Class II medical device cleared by the FDA, is designed for consumer use, providing advanced air filtration technology that can cover up to 800 square feet [4]. - RxAir's technology has been independently tested and proven to destroy over 99.97% of airborne bacteria and viruses, including various strains of influenza and coronaviruses [5]. Start-up Portfolio - Vystar has four start-ups, with GoPaid.com being the most recent addition, which focuses on tokenizing real-world collectibles and fine art, aiming to connect the $62 billion domestic collectibles market with blockchain technology [2][7]. - The tokenization strategy is expected to democratize access to high-value collectibles, allowing multiple investors to own shares of expensive items [7]. Market Potential - The collectibles and fine art tokenization market is projected to reach $16 trillion by 2030, indicating significant growth potential for Vystar's initiatives in this sector [7].

Core Insights - MicroCloud Hologram Inc. has proposed a Quantum Convolutional Neural Network (QCNN) that utilizes hybrid quantum-classical learning, achieving accuracy comparable to classical Convolutional Neural Networks (CNNs) on the MNIST dataset, indicating the practical feasibility of quantum computing in machine learning tasks [1][3][12] Company Overview - MicroCloud Hologram Inc. focuses on providing advanced holographic technology services, including high-precision holographic LiDAR solutions and holographic digital twin technology [15] - The company plans to invest over $400 million in cutting-edge technology sectors, including quantum computing, quantum holography, and artificial intelligence [15] Technological Innovation - The proposed QCNN leverages a hybrid quantum-classical learning framework, combining classical optimizers with quantum circuits to enhance feature extraction and classification tasks [4][11] - The architecture includes a novel Quantum Perceptron model that improves feature extraction and nonlinear mapping capabilities [11] - The quantum circuit employs eight qubits for data encoding and four auxiliary qubits to enhance expressive power, effectively mapping input data for classification [5][11] Application Potential - The QCNN can be applied to various complex datasets and tasks, such as multi-class traffic sign recognition in autonomous driving and multi-class classification of lesions in medical imaging [12][13] - The integration of quantum computing with classical learning offers significant advantages in energy efficiency, parameter efficiency, and computational acceleration for enterprises [13]

Core Insights - NDBT reported net earnings of $2,153,174 or $0.84 per share for the three months ending September 30, 2025, and net earnings of $5,563,832 or $2.17 per share for the nine months ending September 30, 2025 [1][5]. Financial Performance - Interest income for the three months ended September 30, 2025, was $21,679,467, an increase from $19,690,721 in 2024, while for the nine months, it rose to $62,497,724 from $57,809,406 [5]. - Interest expense decreased to $10,511,837 for the three months in 2025 from $11,417,563 in 2024, and for the nine months, it fell to $31,538,242 from $32,759,175 [5]. - Net interest income increased significantly to $11,167,630 for the three months in 2025 from $8,273,158 in 2024, and for the nine months, it rose to $30,959,482 from $25,050,231 [5]. - Noninterest income for the three months was $1,415,333, slightly down from $1,546,280 in 2024, while for the nine months, it increased to $4,555,246 from $4,384,215 [5]. - Noninterest expenses rose to $9,671,275 for the three months in 2025 from $9,302,724 in 2024, and for the nine months, they increased to $28,447,278 from $26,524,077 [5]. - Income before taxes and extraordinary items was $2,577,688 for the three months in 2025, up from $516,714 in 2024, and for the nine months, it increased to $6,627,450 from $2,470,369 [5]. - Total assets as of September 30, 2025, were $1,866,276,212, a slight decrease from $1,867,355,555 in 2024, while total loans increased to $1,281,642,359 from $1,211,656,001 [5]. - Deposits rose to $1,586,843,853 in 2025 from $1,543,618,454 in 2024, and stockholders' equity increased to $179,838,525 from $170,479,567 [5].

Core Insights - Merus N.V. announced interim clinical data for petosemtamab, a bispecific antibody, showing promising response rates in metastatic colorectal cancer (mCRC) patients [1][2][3] Group 1: Clinical Data Summary - In the ongoing phase 2 trial, petosemtamab demonstrated a 100% response rate in first-line (1L) left-sided mCRC patients (n=8) and a 62% response rate in second-line (2L) mCRC patients (n=13) [1][3] - The trial included 54 patients with left- and/or right-sided, KRAS, NRAS, and BRAF wildtype microsatellite stable mCRC, treated with petosemtamab in combination with FOLFOX/FOLFIRI or as monotherapy [3] - In the 1L treatment group, 10 patients were efficacy evaluable, with 8 left-sided patients showing an 80% response rate, including 1 confirmed complete response and 7 partial responses [3][7] Group 2: Mechanism of Action and Potential Impact - Petosemtamab targets both EGFR and LGR5, which may provide a new treatment option for patients with EGFR inhibitor-naïve mCRC [2] - The early results suggest that petosemtamab could become a transformational treatment and a new standard of care for various solid tumors [2] Group 3: Safety Profile - The safety profile of petosemtamab in mCRC appears consistent with its established profile in recurrent/metastatic head and neck squamous cell carcinoma, with no significant overlapping toxicities identified [7] - Infusion-related reactions were managed effectively, with no discontinuations due to these reactions [7]

Core Points - Lassonde Industries Inc. will host a conference call to discuss its Q3 2025 financial results on November 7, 2025 [1] - The call will be led by CEO Vince Timpano and CFO Eric Gemme, and is open to investors, analysts, and interested parties [1] - A live audio broadcast will be available on the company's website, with a replay accessible until November 14, 2025 [1][2] Company Overview - Lassonde Industries Inc. is a leader in the North American food and beverage industry, developing, manufacturing, and marketing a wide range of products including fruit juices, specialty foods, and fruit-based snacks [4] - The company distributes over 3,500 unique products across various categories, including shelf-stable, chilled, and frozen formats [4] - Lassonde operates 19 plants in Canada and the United States, employing over 2,900 full-time equivalent employees [6] Go-to-Market Strategy - The company's strategy includes retail sales to food retailers and wholesalers, as well as food service sales to restaurants, hotels, hospitals, and schools [5]

Core Points - Park Ha Biological Technology Co., Ltd. will change its ticker symbol from "PHH" to "BYAH" effective October 28, 2025 [1][2] - The change is intended to prevent confusion with a delisted company that previously used the same symbol and aims to enhance the Company's long-term brand influence and value [2] Company Overview - Established in 2016, Park Ha Biological Technology Co., Ltd. focuses on developing its private skincare label and promoting direct skincare product sales and franchise alliances under the brand "Park Ha" [4] - As of April 30, 2025, the Company operates three directly operated stores and has 39 franchisees in China, with 38 operating under "Park Ha" and one under "Geni" [4] - The Company offers a "light beauty experience," a complimentary after-sales beauty service in its stores, to add value to its products [4]